Equities research analysts expect Viveve Medical Inc (NASDAQ:VIVE) to report sales of $5.30 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Viveve Medical’s earnings. The highest sales estimate is $5.70 million and the lowest is $4.37 million. Viveve Medical posted sales of $4.07 million in the same quarter last year, which suggests a positive year over year growth rate of 30.2%. The firm is expected to issue its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Viveve Medical will report full-year sales of $21.21 million for the current year, with estimates ranging from $20.14 million to $21.90 million. For the next financial year, analysts expect that the business will report sales of $32.84 million per share, with estimates ranging from $29.12 million to $34.91 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. The company had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $4.97 million. Viveve Medical had a negative return on equity of 568.79% and a negative net margin of 239.33%.
A number of analysts have recently commented on the company. ValuEngine raised Viveve Medical from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Craig Hallum cut Viveve Medical from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Finally, Stifel Nicolaus assumed coverage on Viveve Medical in a research note on Tuesday, April 17th. They issued a “buy” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.20.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Viveve Medical by 135.1% during the 4th quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock worth $188,000 after purchasing an additional 21,683 shares in the last quarter. LMR Partners LLP bought a new stake in Viveve Medical during the 2nd quarter worth approximately $112,000. Spark Investment Management LLC bought a new stake in Viveve Medical during the 1st quarter worth approximately $208,000. BlackRock Inc. increased its stake in Viveve Medical by 8.1% during the 1st quarter. BlackRock Inc. now owns 780,591 shares of the company’s stock worth $2,857,000 after purchasing an additional 58,256 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Viveve Medical by 43.4% during the 1st quarter. Northern Trust Corp now owns 252,974 shares of the company’s stock worth $926,000 after purchasing an additional 76,519 shares in the last quarter. 67.35% of the stock is owned by institutional investors and hedge funds.
Shares of VIVE stock traded up $0.13 on Thursday, reaching $2.60. The company had a trading volume of 236,717 shares, compared to its average volume of 202,292. The company has a quick ratio of 6.00, a current ratio of 6.47 and a debt-to-equity ratio of 1.55. Viveve Medical has a 12 month low of $1.60 and a 12 month high of $7.25.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Read More: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.